In vitro studies of tobramycin

Area of Science:

• Microbiology
• Pharmacology
• Infectious Diseases

Background:

• Antibiotic resistance is a growing concern in treating bacterial infections.
• Aminoglycosides like tobramycin and gentamicin are crucial for managing gram-negative infections.

Purpose of the Study:

• To evaluate the in vitro antimicrobial activity of tobramycin.
• To compare tobramycin's efficacy against gram-negative bacilli and gram-positive cocci.
• To assess tobramycin's activity relative to gentamicin sulfate.

Main Methods:

• Testing tobramycin susceptibility against 457 clinical isolates of gram-negative bacilli.
• Testing tobramycin susceptibility against 151 clinical isolates of gram-positive cocci.
• Comparative analysis of tobramycin and gentamicin sulfate activity.

Main Results:

• The vast majority of gram-negative bacilli were inhibited by tobramycin at ≤1.56 µg/mL.
• Few Staphylococcus aureus isolates and no Streptococcus pyogenes or Diplococcus pneumoniae isolates were susceptible.
• Tobramycin demonstrated greater activity than gentamicin sulfate against gram-negative bacilli, particularly Pseudomonas aeruginosa.

Conclusions:

• Tobramycin exhibits potent in vitro activity against a wide range of gram-negative bacilli.
• Tobramycin is a valuable therapeutic option, especially for Pseudomonas aeruginosa infections.
• Cross-resistance exists between tobramycin and gentamicin, but tobramycin offers advantages in specific infections.